Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. IJ Pharmaceutical Research
  4. Articles

  5. Co-treatment of Naringenin and Ketoprofen-RGD Suppresses Cell Proliferation via Calmodulin/PDE/cAMP/PKA Axis Pathway in Leukemia and Ovarian Cancer Cells
  6. Scopus by Title (Ref)

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Clinical and Functional Characterization of PDE1A as a Wnt/β-Catenin-Linked Biomarker of Progression and Platinum Resistance in Epithelial Ovarian Cancer

- Han G.H. , et al.

2. Naringenin: A potential anticancer drug

- Zhang Y. , et al.

3. Cyclic nucleotide phosphodiesterases as drug targets

- Kelly M.P. , et al.

4. PRDX1 depletion predisposes to ferroptosis through inhibiting the cAMP pathway in B-cell acute lymphoblastic leukemia

- Zhong F.F. , et al.

5. Oxidative lipid damage by naringenin selectively sensitizes chronic myeloid leukemia cell lines and patient samples to Bcr-Abl tyrosine kinase inhibitors

- Wang M. , et al.

6. NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer

- Coutinho L.L. , et al.

7. Comprehensive analysis of PDE2A: a novel biomarker for prognostic value and immunotherapeutic potential in human cancers

- Yu Z. , et al.

HomeSearchInstructionsAPC

Archives

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.